Hemsén A, Pernow J, Lundberg J M
Department of Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Acta Physiol Scand. 1991 Mar;141(3):325-34. doi: 10.1111/j.1748-1716.1991.tb09088.x.
Endothelin-like immunoreactivity (ET-LI), mean arterial blood pressure (MABP) and vascular resistance in the spleen, kidney and femoral vascular bed were measured during intravenous infusions (20 pmol.kg-1.min) of endothelin-2 (ET-2), endothelin-3 (ET-3), big endothelin-1 (big ET) and sarafotoxin 6b in the pig. All peptides (especially endothelin-2 and sarafotoxin 6b) caused vasoconstrictor effects in the kidney. Endothelin-2, endothelin-3 and sarafotoxin 6b also evoked significant increases in splenic and femoral vascular resistance. The relative vasoconstrictor response to endothelin-2 was larger in the kidney and spleen than in the femoral vascular bed whereas the opposite was observed for endothelin-3. A high degree of plasma clearance for endothelin-like immunoreactivity was observed. Thus, for ET-2 and ET-3 about 70% of arterial endothelin-like immunoreactivity was removed over the kidney while over the spleen and femoral vascular bed an extraction of 50% for plasma endothelin-2 and 30-40% for endothelin-3 was observed. Big endothelin-1 was only extracted by 34% over the kidney and not at all in the splenic or femoral vascular bed. The metabolic plasma half-lifes of endothelin-2 and endothelin-3 in vivo were in the same range, 1-2 minutes, whereas the half-life of big endothelin-1 was 9 minutes. HPLC-characterization of the plasma endothelin-like immunoreactivity during and after big endothelin-1 infusion as well as measurements using a specific endothelin-1 antiserum revealed formation of endothelin-1 from circulating big endothelin-1 in vivo but not in plasma in vitro. It is concluded that there exists specificity concerning the vasoconstrictor effects and the removal of endothelin-peptides from the circulation, both mechanisms being most prominent in the kidney. Big endothelin-1 has a much longer metabolic half-life, less regional clearance and poor vasoconstrictor activity compared with endothelin-1. Furthermore, endothelin-1 is formed from circulating big endothelin-1 probably by an endothelin-converting enzyme.
在猪静脉输注内皮素 -2(ET -2)、内皮素 -3(ET -3)、大内皮素 -1(big ET)和芋螺毒素 6b(20 pmol·kg⁻¹·min)期间,测量了脾脏、肾脏和股血管床中的内皮素样免疫反应性(ET -LI)、平均动脉血压(MABP)和血管阻力。所有肽类(尤其是内皮素 -2 和芋螺毒素 6b)均在肾脏中引起血管收缩效应。内皮素 -2、内皮素 -3 和芋螺毒素 6b 还引起脾脏和股血管阻力显著增加。内皮素 -2 引起的相对血管收缩反应在肾脏和脾脏中比在股血管床中更大,而内皮素 -3 则相反。观察到内皮素样免疫反应性具有较高的血浆清除率。因此,对于 ET -2 和 ET -3,约 70%的动脉内皮素样免疫反应性在肾脏中被清除,而在脾脏和股血管床中,血浆内皮素 -2 的提取率为 50%,内皮素 -3 的提取率为 30 - 40%。大内皮素 -1 在肾脏中的提取率仅为 34%,在脾脏或股血管床中则完全不被提取。内皮素 -2 和内皮素 -3 在体内的代谢血浆半衰期在相同范围内,为 1 - 2 分钟,而大内皮素 -1 的半衰期为 9 分钟。大内皮素 -1 输注期间及之后血浆内皮素样免疫反应性的高效液相色谱表征以及使用特异性内皮素 -1 抗血清的测量结果显示,体内循环中的大内皮素 -1 可形成内皮素 -1,但体外血浆中则不会。结论是,内皮素肽的血管收缩效应和从循环中的清除存在特异性,这两种机制在肾脏中最为显著。与内皮素 -1 相比,大内皮素 -1 的代谢半衰期长得多,区域清除率较低,血管收缩活性较差。此外,内皮素 -1 可能由循环中的大内皮素 -1 通过内皮素转换酶形成。